Last reviewed · How we verify
NCT02432625
BBD Longitudinal Study of Osteogenesis Imperfecta
trial in Osteogenesis Imperfecta in 1,000 participants. Currently enrolling.
31 August 2030
Quick facts
| Lead sponsor | Baylor College of Medicine |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 June 2015 |
| Primary completion | 31 August 2030 |
| Estimated completion | 31 December 2031 |
| Sites | 12 locations across Canada, United States |
Conditions studied
- Osteogenesis Imperfecta — all drugs for Osteogenesis Imperfecta →
Sponsor
Baylor College of Medicine
Who can join
Eligibility, any sex, with Osteogenesis Imperfecta. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal stature, and normal lifespan. Fractures can occur in any bone, but are most common in the extremities. These disorders can be devastating and progressive and result in deformity, chronic pain, impaired function and loss of quality of life. The overall goal of this study is to answer specific question about the natural history of brittle bone diseases as defined by molecular etiology and to develop the foundation for prospective clinical studies.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pediatric Outcomes Data Collection Instrument is a Useful Patient-Reported Outcome Measure for Physical Function in Children with Osteogenesis Imperfecta.
Murali CN, Cuthbertson D, Slater B, Nguyen D, et al · · 2020 · cited 18× · PMID 31772349 · DOI 10.1038/s41436-019-0688-6 -
A multicenter study to evaluate pain characteristics in osteogenesis imperfecta.
Rodriguez Celin M, Kruger KM, Caudill A, Murali CN, et al · · 2023 · cited 17× · PMID 36271817 · DOI 10.1002/ajmg.a.63009 -
The IFITM5 mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect.
Marom R, Song IW, Busse EC, Washington ME, et al · · 2024 · cited 9× · PMID 38885336 · DOI 10.1172/jci170369 -
Health-related quality of life in adults with osteogenesis imperfecta.
Murali CN, Slater B, Musaad S, Cuthbertson D, et al · · 2021 · cited 9× · PMID 33580568 · DOI 10.1111/cge.13939 -
Alterations of a serum marker of collagen X in growing children with osteogenesis imperfecta.
Nicol LE, Coghlan RF, Cuthbertson D, Nagamani SCS, et al · · 2021 · cited 6× · PMID 33932621 · DOI 10.1016/j.bone.2021.115990 -
Cross-sectional and longitudinal analysis of bone age maturation during peri-pubertal growth in children with type I, III and IV osteogenesis imperfecta.
Nicol LE, Baines H, Koike S, Liu W, et al · · 2024 · cited 3× · PMID 38969279 · DOI 10.1016/j.bone.2024.117192 -
CORR Insights®: Cardiopulmonary Status in Adults with Osteogenesis Imperfecta: Intrinsic Lung Disease May Contribute More Than Scoliosis.
Gerdhem P. · · 2020 · PMID 32925237 · DOI 10.1097/corr.0000000000001469
Verify or expand the search:
- PubMed search for NCT02432625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteogenesis Imperfecta
Currently open trials in the same condition.
- NCT07366086 — Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta · Phase 3 · recruiting
- NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting
- NCT05972551 — Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Oste · Phase 3 · recruiting
- NCT05927389 — Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta · NA · recruiting
- NCT06193642 — Increasing Knowledge on Osteogenesis Imperfecta by Collecting Epidemiological Data · NA · active not recruiting
Other Baylor College of Medicine trials
Trials by the same sponsor.
- NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
- NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
- NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
- NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
- NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02432625 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02432625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing